GKOS (Glaukos) Beginning Cash Position: $94.6 Mil (As of Mar. 2026)


GKOS Glaukos Corp GKOS
79 GF Score
Price $148.34
GF Value $135.92
Valuation Fairly Valued
! 6 Warning Signs
View Full Analysis

What is Glaukos Beginning Cash Position?

Glaukos GKOS +7.83% 79 Beginning Cash Position is $94.6 Mil as of Mar. 2026. GuruFocus rates GKOS with a GF Score™ of 79/100 and a GF Value™ of $135.92 (Fairly Valued). The stock has 6 warning signs investors should review.

Glaukos's Beginning Cash Position for the quarter that ended in Mar. 2026 was $94.6 Mil.

Glaukos's quarterly Beginning Cash Position declined from Sep. 2025 ($104.6 Mil) to Dec. 2025 ($102.1 Mil) and declined from Dec. 2025 ($102.1 Mil) to Mar. 2026 ($94.6 Mil).

Glaukos's annual Beginning Cash Position declined from Dec. 2023 ($126.6 Mil) to Dec. 2024 ($99.3 Mil) but then increased from Dec. 2024 ($99.3 Mil) to Dec. 2025 ($174.4 Mil).

Glaukos Beginning Cash Position Related Terms

Glaukos Beginning Cash Position Historical Data

* Premium members only.

The historical data trend for Glaukos's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Glaukos Beginning Cash Position Chart

Glaukos Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beginning Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 106.16 110.12 126.60 99.32 174.36

Glaukos Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beginning Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 174.36 118.99 104.65 102.08 94.65
GKOS
79GF Score
Glaukos Corp GKOS
Beginning Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Glaukos Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

What does a Beginning Cash Position of $94.6 Mil mean?
Glaukos (GKOS) has a Beginning Cash Position of $94.6 Mil as of Mar. 2026. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Glaukos and its competitors.
Is Glaukos' Beginning Cash Position too high?
Glaukos' current Beginning Cash Position is $94.6 Mil. Overall, Glaukos has a GF Score™ of 79/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Glaukos' Beginning Cash Position compare to BIO and BRKR?
Glaukos' Beginning Cash Position of $94.6 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for a Medical Devices & Instruments company?
A good Beginning Cash Position depends on the Medical Devices & Instruments industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Glaukos and its competitors. Glaukos's current Beginning Cash Position is $94.6 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Glaukos stock overvalued right now?
Based on GuruFocus' analysis, Glaukos (GKOS) is currently considered Fairly Valued. The stock's GF Value™ is $135.92, compared to a current price of $148.34 — trading 9.1% above its estimated fair value. The current Beginning Cash Position is $94.6 Mil. Glaukos' overall GF Score™ is 79/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For Glaukos (GKOS), the current Beginning Cash Position is $94.6 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Glaukos (GKOS) Overvalued in 2026?

Based on GuruFocus' analysis, Glaukos stock appears to be overvalued. The current stock price of $148.34 is trading 9.1% above its estimated GF Value™ of $135.92. GuruFocus considers Glaukos to be Fairly Valued.

Key valuation signals for GKOS:

  • Beginning Cash Position: $94.6 Mil
  • GF Value™: $135.92 vs. price of $148.34 (9.1% above fair value)
  • GF Score™: 79/100 with 6 warning signs

No single metric tells the full story. See the GKOS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Glaukos Business Description

Other Exchanges 6GJ:Germany
Address One Glaukos Way, Aliso Viejo, CA, USA, 92656
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.
79GF Score

Get the complete analysis for GKOS

Beginning Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$148.34
Price
$135.92
GF Value